BrainStorm Cell Therapeutics Presents New Analyses from NurOwn's Phase 3 ALS Trial at the 21st Annual NEALS Meeting

/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the...

Related Keywords

Massachusetts ,United States ,California ,University Of Massachusetts Medical School ,Irvine ,John Mullaly ,Anthony Windebank ,Robert Brown ,Namita Goyal ,Robert Baloh ,Seanm Healey ,Robert Miller ,Jonathan Katz ,Matthew Burford ,Lisa Guiterman ,Stacy Lindborg ,James Berry ,Brainstorm Cell Therapeutics Inc ,California Institute For Regenerative Medicine ,Lifesci Advisors ,Drug Administration ,Harvard Medical School ,Nasdaq ,University Of Massachusetts Medical School Prof ,Research Symposium ,Sinai Medical Center Dr ,National Ms Society ,European Medicines Agency ,California Pacific Medical Center Prof ,University Of California Irvine Dr ,Brainstorm Cell Therapeutics ,Rating Scale ,Further Analysis ,Nurown Phase ,Clearwater Beach ,Stacy Lindborg Phd ,Executive Vice President ,Chief Development Officer ,Merit Cudkowicz ,Massachusetts General Hospital ,Julieanne Dorn Professor ,Massachusetts General ,Town Phase ,Patient Population ,Total Score Threshold ,Item Level Threshold ,Gross Motor ,Town Study ,California Irvine ,Cedars Sinai Medical Center ,California Pacific Medical Center ,Massachusetts Medical School ,Mayo Clinic ,Nathan Staff ,Storm Cell Therapeutics ,Orphan Drug ,California Institute ,Regenerative Medicine ,Harbor Statement ,Sci Advisors ,